Related content

Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review

By  

Current Clinical Pharmacology, Vol. 5, Iss. 3, 2010-08 ,pp. : 209-217

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping

By Innocenti Federico   Ratain Mark J  

Pharmacogenomics, Vol. 7, Iss. 8, 2006-12 ,pp. : 1211-1221

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan

By Ando Maki   Hasegawa Yoshinori   Ando Yuichi  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 539-545

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide

By  

Current Drug Metabolism, Vol. 7, Iss. 4, 2006-05 ,pp. : 431-454

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity

By  

Current Drug Metabolism, Vol. 12, Iss. 10, 2011-12 ,pp. : 932-943

Bentham Science Publishers

Access to resources Recommend Favorite